Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6Diarrhea 4Rectal Neoplasms 2Ovarian Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Short Bowel Syndrome 1Neoplasms 1Melanoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Exanthema 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Colitis, Ulcerative 1Colitis 1Chemotherapy-related Diarrhea 1

Interventions

Cisplatin 86Radiotherapy 71Paclitaxel 50Fluorouracil 38Carboplatin 36Drug Therapy 32Neoadjuvant Therapy 23toripalimab 19tislelizumab 18pembrolizumab 17camrelizumab 17Irinotecan 17Esophagectomy 17Surgical Procedures, Operative 16Radiation 16Docetaxel 16sintilimab 15Oxaliplatin 14130-nm albumin-bound paclitaxel 14nimotuzumab 11TP protocol 11S 1 (combination) 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Capecitabine 11Albumin-Bound Paclitaxel 10apatinib 9Leucovorin 9Immune Checkpoint Inhibitors 8nedaplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Squamous Cell Carcinoma × Loperamide × Clear all
NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡